Telavancin versus Vancomycin for Hospital- Acquired Pneumonia due to Gram-positive

H. David Friedl
A Martin E. Stryjewski
For The Attain Study Groupb

Publication date

September 2016

Abstract

Background. Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. Methods. Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients wit

Extracted data

We use cookies to provide a better user experience.

Data Protection

Telavancin versus Vancomycin for Hospital- Acquired Pneumonia due to Gram-positive

Abstract

Extracted data

Telavancin versus Vancomycin for Hospital- Acquired Pneumonia due to Gram-positive

Abstract

Extracted data

Related items

Related items